Dupixent helps put Sanofi back on growth track

They think the asthma indication could be worth $2.5bn on its own, although it’s a crowded market with GlaxoSmithKline’s Nucala (mepolizumab), Teva’s Cinqair (reslizumab) and AstraZeneca’s

Amgen CEO says Aimovig is “one of most successful launches”

The strong take-up has come despite approvals for rival CGRP inhibitors from Teva and Lilly, and Amgen says its first-mover advantage is backed up by a patient-friendly delivery

AstraZeneca chief on Brexit: “it’s going to be really painful”

That disparity – which Soriot says is “annoying” - may be a reason for the rumour last year that he was planning to jump ship to Teva, which he dismisses in the interview ... Teva’s vacant CEO role eventually filled by Lundbeck’s Kåre Schultz.

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 (Next 4)